PetCure reaches 10,000 treated pets in radiation therapy milestone
CURRENT BRIEF VERSION: PetCure Oncology says it has now treated 10,000 pets with radiation therapy since launching in 2015, a milestone the company is framing as evidence that advanced radiation has moved beyond a niche academic offering and into a broader referral option for community veterinarians. In its January 7, 2026 announcement, the Thrive Pet Healthcare-affiliated provider said it now operates eight treatment centers nationwide and supports referrals with 12 board-certified oncologists and eight supervising veterinarians. The company said its stereotactic radiosurgery and stereotactic radiation therapy model often allows treatment in one to three sessions, compared with the longer historical course of conventional radiation. Company leaders have also tied that shorter-course approach directly to access, noting that many families live hours from a radiation facility and that compressed protocols can make referral more realistic outside major population centers. (petcureoncology.com)
Why it matters: For veterinary professionals, the milestone is less about a round number than what it signals about referral access. Radiation oncology has long been constrained by geography, equipment costs, and specialist availability, and recent reviews still describe stereotactic radiotherapy as a modality that requires specialized equipment and expertise. PetCure’s scale suggests more primary care teams may now have a practical pathway for discussing radiation earlier in the cancer workup, especially for cases where fewer anesthetic events and shorter treatment timelines could make referral more feasible for pet parents. PetCure has also pointed to newer access-oriented trends, including compact self-contained radiation units that may not require a dedicated vault and could potentially allow CT, treatment planning, and treatment delivery under a single anesthetic event. (petcureoncology.com)
What to watch: Watch whether this milestone is followed by additional center expansion, more mobile or compact radiation platforms, and more published outcomes data that could further normalize earlier radiation referrals in practice. Also worth watching: whether radiation’s role broadens beyond current stereotactic use cases, including combination work with immunotherapy, low-dose radiation for chronic inflammatory conditions, and low dose-rate radiation therapy in canine B-cell lymphoma, where PetCure says early peer-reviewed data have shown improved survival when added during induction chemotherapy. (petcureoncology.com)